Stockreport

Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing [Yahoo! Finance]

Arcturus Therapeutics Holdings Inc.  (ARCT) 
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arcturusrx.com/investor-relations
PDF well-tolerated and showed early biological signals (reduced mucus plugging), and is preparing a 12-week Phase 2 to more directly assess lung function. The 12-week stud [Read more]